DISQUS

Ogan Gurel, MD · 2 years ago

One of the interesting aspects of diagnostic tests for prospectively assessing patient response to psychiatric medications is not so much personalized medicine (although this "buzz" word does generate investor interest) but rather that such medications (particularly antipsychotics and antidepressants) have a relatively long lag time (sometimes several weeks) before a response can be observed. Hence, this is more a matter of accelerating the treatment effect which improves clinical efficacy, patient convenience and also optimizes physician/clinical resources. In my mind, these are probably the most significant benefits to such technology.

Another way of putting it is that this TheraGenetics technology promises to improve the operational efficiency of the treatment rather than any particular "personalization" per se.

For more on personalized medicine see the Life Sciences Daily blog at:

http://blog.aesisgroup.com/categories/Personali...

Ogan